The polypill could become part of a worldwide treatment strategy, said Fuster, to help prevent recurrent cardiovascular events in patients who have had a heart attack.

The polypill reduced the primary composite risk of cardiovascular death, nonfatal type 1 MI, nonfatal ischemic stroke, and urgent revascularization by a relative 24% over usual care, with a rate ...

In 2022, a large U.S.-based study examined whether a daily polypill could benefit people who have already had a heart attack or stroke (and are therefore at very high risk of having another one).

HEART HEALTH Combo 'polypill' cuts heart disease deaths, new study finds 'Three-in-one' drug may play role in preventing cardiovascular events in certain patients, study says ...

Older heart disease patients who took a combination “polypill” made up of three different medications had a lower risk of major cardiovascular events, according to a new study published Friday ...

The polypill is a combination medication that contains multiple active ingredients in a single pill, typically tailored for individuals at high risk of cardiovascular diseases.

The polypill used in the study has not been approved by the Food and Drug Administration and is not available to patients in the United States right now. Dr. Fuster said the results of the new ...

An inexpensive polypill is probably one of the best ways to solve the world’s heart problems, cardiologists say. This approach to medication for heart disease, which experts say could save ...

The FDA approved a polypill containing telmisartan, amlodipine, and indapamide, known as Widaplik, for the treatment of hypertension in adults, including as initial treatment. This marks the first ...

The polypill was also favorable in other measures studied in the trial, such as stroke or myocardial infarction. The polypill and trial come after 15 years of work, Fuster said.